Comparison of PFOA and PFOS concentrations in uremic patients (n = 126) before (pre HD) and after HD (post HD) (ng/ml) (p = 0.707 for PFOA, p = 0.001 for PFOS) (* compared with pre-HD value with paired t–test, p<0.05).

<p>Comparison of PFOA and PFOS concentrations in uremic patients (n = 126) before (pre HD) and after HD (post HD) (ng/ml) (p = 0.707 for PFOA, p = 0.001 for PFOS) (* compared with pre-HD value with paired t–test, p<0.05).</p

Relationship of age and dialysis profiles of to serum concentrations of PFOA and PFOS in uremic patients using linear regression (n = 126).

<p>Relationship of age and dialysis profiles of to serum concentrations of PFOA and PFOS in uremic patients using linear regression (n = 126).</p

Linear regression of ferritin (ng/ml) (p<0.001) (A), mean corpuscular volume (MCV) (fl) (p = 0.023) (B), protein (g/dl) (p = 0.005) (C) and Ca (mg/dl) (p = 0.012) (D) (X axis) with serum PFOS concentration (ng/ml) (Y axis) (all p <0.05).

<p>Linear regression of ferritin (ng/ml) (p<0.001) (A), mean corpuscular volume (MCV) (fl) (p = 0.023) (B), protein (g/dl) (p = 0.005) (C) and Ca (mg/dl) (p = 0.012) (D) (X axis) with serum PFOS concentration (ng/ml) (Y axis) (all p <0.05).</p

Linear regression of hemodialysis (HD) duration (hours) (p = 0.029) (A), Karnofsky performance status score for activities of daily living (ADL) (p = 0.008) (B), serum cholesterol (mg/dl) (p = 0.011) (C) and chloride (Cl) (mEq/L) (p = 0.013) (D) (X-axis) with serum PFOS concentration (ng/ml) (Y-axis) (all p <0.05).

<p>Linear regression of hemodialysis (HD) duration (hours) (p = 0.029) (A), Karnofsky performance status score for activities of daily living (ADL) (p = 0.008) (B), serum cholesterol (mg/dl) (p = 0.011) (C) and chloride (Cl) (mEq/L) (p = 0.013) (D) (X-axis) with serum PFOS concentration (ng/ml) (Y-axis) (all p <0.05).</p

Comparisons of patient data and medication profiles with PFOA and PFOS levels in different subgroups of uremic patients using the independent t-test (n = 126).

<p>Comparisons of patient data and medication profiles with PFOA and PFOS levels in different subgroups of uremic patients using the independent t-test (n = 126).</p

Kaplan–Meier survival analysis of baseline LMR in NPC patients.

<p>A. OS curves for LMR; B. DFS curves for LMR; C. DMFS curves for LMR; D. LRRFS curves for LMR. LMR, lymphocyte-to-monocyte ratio; NPC, nasopharyngeal carcinoma; OS, overall survival; DFS, disease-free survival; DMFS, distant metastasis-free survival; LRRFS, loco-regional recurrence-free survival.</p

Relationship of hemogram and biochemical profiles to serum concentrations of PFOA and PFOS in uremic patients using linear regression.

<p>Relationship of hemogram and biochemical profiles to serum concentrations of PFOA and PFOS in uremic patients using linear regression.</p

Multivariate analysis of independent prognostic factors for patients with nasopharyngeal carcinoma (n = 1547).

<p>Abbreviation: OS  =  Overall Survival; DFS  =  Disease-Free Survival; DMFS  =  Distant Metastasis-Free Survival; LRRFS  =  Loco-Regional Recurrence-Free Survival; CRT  =  chemoradiotherapy; RT  =  radiotherapy; LMR  =  lymphocyte-to-monocyte ratio; HR  =  Hazard Ratio, derived from COX proportional hazard model. In this analysis, T status, N status and tumor stage were divided into two groups. For T status: T1-2 and T3-4; for N status:N0-1 and N2-3; for tumor stage: I–II and III–IV.</p

Kaplan–Meier survival analysis of baseline lymphocyte count (LY) in NPC patients.

<p>A. OS curves for LY; B. DFS curves for LY; C. DMFS curves for LY; D. LRRFS curves for LY. LY, lymphocyte count; NPC, nasopharyngeal carcinoma; OS, overall survival; DFS, disease-free survival; DMFS, distant metastasis-free survival; LRRFS, loco-regional recurrence-free survival.</p

Univariate analysis of prognostic factors for patients with nasopharyngeal carcinoma.

<p>Abbreviation: OS  =  Overall Survival; DFS  =  Disease-Free Survival; DMFS  =  Distant Metastasis-Free Survival; LRRFS  =  Loco-Regional Recurrence-Free Survival; CRT  =  chemoradiotherapy; RT =  radiotherapy; LMR  =  lymphocyte-to-monocyte ratio; HR  =  Hazard Ratio, derived from COX proportional hazard model.</p